Adial Pharmaceuticals, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Adial Pharmaceuticals, Inc. (ADIL) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $258.59 thousand as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2021-11-15
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $258.59K.
- 2021-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $270.73K.
- 2021-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $282.63K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2021-09-30 | $258.59K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $270.73K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $282.63K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |